170 related articles for article (PubMed ID: 20843686)
21. Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors.
Scheiper B; Matter H; Steinhagen H; Böcskei Z; Fleury V; McCort G
Bioorg Med Chem Lett; 2011 Sep; 21(18):5480-6. PubMed ID: 21840218
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of potent, isoxazole-containing renin inhibitors.
Fournier PA; Arbour M; Cauchon E; Chen A; Chefson A; Ducharme Y; Falgueyret JP; Gagné S; Grimm E; Han Y; Houle R; Lacombe P; Lévesque JF; MacDonald D; Mackay B; McKay D; Percival MD; Ramtohul Y; St-Jacques R; Toulmond S
Bioorg Med Chem Lett; 2012 Apr; 22(8):2670-4. PubMed ID: 22450130
[TBL] [Abstract][Full Text] [Related]
23. Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds.
Matter H; Scheiper B; Steinhagen H; Böcskei Z; Fleury V; McCort G
Bioorg Med Chem Lett; 2011 Sep; 21(18):5487-92. PubMed ID: 21840215
[TBL] [Abstract][Full Text] [Related]
24. Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.
Berlin M; Ting PC; Vaccaro WD; Aslanian R; McCormick KD; Lee JF; Albanese MM; Mutahi MW; Piwinski JJ; Shih NY; Duguma L; Solomon DM; Zhou W; Sher R; Favreau L; Bryant M; Korfmacher WA; Nardo C; West RE; Anthes JC; Williams SM; Wu RL; Susan She H; Rivelli MA; Corboz MR; Hey JA
Bioorg Med Chem Lett; 2006 Feb; 16(4):989-94. PubMed ID: 16297617
[TBL] [Abstract][Full Text] [Related]
25. Piperidine renin inhibitors: from leads to drug candidates.
Märki HP; Binggeli A; Bittner B; Bohner-Lang V; Breu V; Bur D; Coassolo PH; Clozel JP; D'Arcy A; Doebeli H; Fischli W; Funk CH; Foricher J; Giller T; Grüninger F; Guenzi A; Güller R; Hartung T; Hirth G; Jenny CH; Kansy M; Klinkhammer U; Lave T; Lohri B; Luft FC; Mervaala EM; Müller DN; Müller M; Montavon F; Oefner CH; Qiu C; Reichel A; Sanwald-Ducray P; Scalone M; Schleimer M; Schmid R; Stadler H; Treiber A; Valdenaire O; Vieira E; Waldmeier P; Wiegand-Chou R; Wilhelm M; Wostl W; Zell M; Zell R
Farmaco; 2001; 56(1-2):21-7. PubMed ID: 11347960
[TBL] [Abstract][Full Text] [Related]
26. Impact of passive permeability and gut efflux transport on the oral bioavailability of novel series of piperidine-based renin inhibitors in rodents.
Lévesque JF; Bleasby K; Chefson A; Chen A; Dubé D; Ducharme Y; Fournier PA; Gagné S; Gallant M; Grimm E; Hafey M; Han Y; Houle R; Lacombe P; Laliberté S; MacDonald D; Mackay B; Papp R; Tschirret-Guth R
Bioorg Med Chem Lett; 2011 Sep; 21(18):5547-51. PubMed ID: 21784634
[TBL] [Abstract][Full Text] [Related]
27. Novel 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin.
Göschke R; Stutz S; Rasetti V; Cohen NC; Rahuel J; Rigollier P; Baum HP; Forgiarini P; Schnell CR; Wagner T; Gruetter MG; Fuhrer W; Schilling W; Cumin F; Wood JM; Maibaum J
J Med Chem; 2007 Oct; 50(20):4818-31. PubMed ID: 17824679
[TBL] [Abstract][Full Text] [Related]
28. (4-Piperidinyl)-piperazine: a new platform for acetyl-CoA carboxylase inhibitors.
Chonan T; Oi T; Yamamoto D; Yashiro M; Wakasugi D; Tanaka H; Ohoka-Sugita A; Io F; Koretsune H; Hiratate A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6645-8. PubMed ID: 19853443
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of disubstituted (4-piperidinyl)-piperazine derivatives as potent acetyl-CoA carboxylase inhibitors.
Chonan T; Tanaka H; Yamamoto D; Yashiro M; Oi T; Wakasugi D; Ohoka-Sugita A; Io F; Koretsune H; Hiratate A
Bioorg Med Chem Lett; 2010 Jul; 20(13):3965-8. PubMed ID: 20537533
[TBL] [Abstract][Full Text] [Related]
30. Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors.
Imaeda Y; Tawada M; Suzuki S; Tomimoto M; Kondo M; Tarui N; Sanada T; Kanagawa R; Snell G; Behnke CA; Kubo K; Kuroita T
Bioorg Med Chem; 2016 Nov; 24(22):5771-5780. PubMed ID: 27687967
[TBL] [Abstract][Full Text] [Related]
31. Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4'-piperidine] based melanocortin subtype-4 receptor agonists.
Guo L; Ye Z; Liu J; He S; Bakshi RK; Sebhat IK; Dobbelaar PH; Hong Q; Jian T; Dellureficio JP; Tsou NN; Ball RG; Weinberg DH; MacNeil T; Tang R; Tamvakopoulos C; Peng Q; Chen HY; Chen AS; Martin WJ; MacIntyre DE; Strack AM; Fong TM; Wyvratt MJ; Nargund RP
Bioorg Med Chem Lett; 2010 Aug; 20(16):4895-900. PubMed ID: 20621473
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and SAR of piperidyl-oxadiazoles as 11β-hydroxysteroid dehydrogenase 1 inhibitors.
Xia G; You X; Liu L; Liu H; Wang J; Shi Y; Li P; Xiong B; Liu X; Shen J
Eur J Med Chem; 2013 Apr; 62():1-10. PubMed ID: 23353742
[TBL] [Abstract][Full Text] [Related]
33. Discovery of a series of aminopiperidines as novel iNOS inhibitors.
Le Bourdonnec B; Leister LK; Ajello CA; Cassel JA; Seida PR; O'Hare H; Gu M; Chu GH; Tuthill PA; DeHaven RN; Dolle RE
Bioorg Med Chem Lett; 2008 Jan; 18(1):336-43. PubMed ID: 18024030
[TBL] [Abstract][Full Text] [Related]
34. Direct renin inhibitors as a new therapy for hypertension.
Webb RL; Schiering N; Sedrani R; Maibaum J
J Med Chem; 2010 Nov; 53(21):7490-520. PubMed ID: 20731374
[No Abstract] [Full Text] [Related]
35. Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile.
Tokuhara H; Imaeda Y; Fukase Y; Iwanaga K; Taya N; Watanabe K; Kanagawa R; Matsuda K; Kajimoto Y; Kusumoto K; Kondo M; Snell G; Behnke CA; Kuroita T
Bioorg Med Chem; 2018 Jul; 26(12):3261-3286. PubMed ID: 29754833
[TBL] [Abstract][Full Text] [Related]
36. Discovery and structure-activity relationships of novel piperidine inhibitors of farnesyltransferase.
Nara S; Tanaka R; Eishima J; Hara M; Takahashi Y; Otaki S; Foglesong RJ; Hughes PF; Turkington S; Kanda Y
J Med Chem; 2003 Jun; 46(12):2467-73. PubMed ID: 12773050
[TBL] [Abstract][Full Text] [Related]
37. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin.
Rahuel J; Rasetti V; Maibaum J; Rüeger H; Göschke R; Cohen NC; Stutz S; Cumin F; Fuhrer W; Wood JM; Grütter MG
Chem Biol; 2000 Jul; 7(7):493-504. PubMed ID: 10903938
[TBL] [Abstract][Full Text] [Related]
38. Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets.
Maibaum J; Stutz S; Göschke R; Rigollier P; Yamaguchi Y; Cumin F; Rahuel J; Baum HP; Cohen NC; Schnell CR; Fuhrer W; Gruetter MG; Schilling W; Wood JM
J Med Chem; 2007 Oct; 50(20):4832-44. PubMed ID: 17824680
[TBL] [Abstract][Full Text] [Related]
39. Exploring Left-Hand-Side substitutions in the benzoxazinone series of 4-amino-piperidine bacterial type IIa topoisomerase inhibitors.
Geng B; Comita-Prevoir J; Eyermann CJ; Reck F; Fisher S
Bioorg Med Chem Lett; 2011 Sep; 21(18):5432-5. PubMed ID: 21782427
[TBL] [Abstract][Full Text] [Related]
40. Ketopiperazine-based renin inhibitors: optimization of the "C" ring.
Holsworth DD; Cai C; Cheng XM; Cody WL; Downing DM; Erasga N; Lee C; Powell NA; Edmunds JJ; Stier M; Jalaie M; Zhang E; McConnell P; Ryan MJ; Bryant J; Li T; Kasani A; Hall E; Subedi R; Rahim M; Maiti S
Bioorg Med Chem Lett; 2006 May; 16(9):2500-4. PubMed ID: 16480874
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
